211 related articles for article (PubMed ID: 34329579)
1. Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions.
Bennett CL; Focosi D; Socal MP; Bian JC; Nabhan C; Hrushesky WJ; Bennett AC; Schoen MW; Berger JR; Armitage JO;
Lancet Haematol; 2021 Aug; 8(8):e593-e604. PubMed ID: 34329579
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
[TBL] [Abstract][Full Text] [Related]
3. Progressive Multifocal Leukoencephalopathy Following Treatment with Rituximab in an HIV-Negative Patient with Non-Hodgkin Lymphoma. A Case Report and Literature Review.
Felli V; Di Sibio A; Anselmi M; Gennarelli A; Sucapane P; Splendiani A; Catalucci A; Marini C; Gallucci M
Neuroradiol J; 2014 Dec; 27(6):657-64. PubMed ID: 25489887
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.
Berger JR; Malik V; Lacey S; Brunetta P; Lehane PB
J Neurovirol; 2018 Jun; 24(3):323-331. PubMed ID: 29508305
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab.
Focosi D; Tuccori M; Maggi F
Rev Med Virol; 2019 Nov; 29(6):e2077. PubMed ID: 31369199
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: A case report and literature review.
Al-Tawfiq JA; Banda RW; Daabil RA; Dawamneh MF
J Infect Public Health; 2015; 8(5):493-7. PubMed ID: 25666327
[TBL] [Abstract][Full Text] [Related]
7. An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma.
Muto R; Sugita Y; Momosaki S; Ito Y; Wakugawa Y; Ohshima K
Neuropathology; 2019 Feb; 39(1):58-63. PubMed ID: 30511425
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.
Clifford DB; Ances B; Costello C; Rosen-Schmidt S; Andersson M; Parks D; Perry A; Yerra R; Schmidt R; Alvarez E; Tyler KL
Arch Neurol; 2011 Sep; 68(9):1156-64. PubMed ID: 21555606
[TBL] [Abstract][Full Text] [Related]
9. Rituximab-associated progressive multifocal leukoencephalopathy.
Sokol J; Lisá L; Zeleňáková J; Balhárek T; Plameňová I; Staško J; Kubisz P
Vnitr Lek; 2017; 63(1):60-64. PubMed ID: 28225293
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Carson KR; Evens AM; Richey EA; Habermann TM; Focosi D; Seymour JF; Laubach J; Bawn SD; Gordon LI; Winter JN; Furman RR; Vose JM; Zelenetz AD; Mamtani R; Raisch DW; Dorshimer GW; Rosen ST; Muro K; Gottardi-Littell NR; Talley RL; Sartor O; Green D; Major EO; Bennett CL
Blood; 2009 May; 113(20):4834-40. PubMed ID: 19264918
[TBL] [Abstract][Full Text] [Related]
11. Progressive Multifocal Leukoencephalopathy Among Ibrutinib Treatment In Chronic Lymphocytic Leukemia.
Çetintepe T; Gediz F; Akyar I; Çetintepe L; Koç AM
J Oncol Pharm Pract; 2022 Jul; 28(5):1249-1253. PubMed ID: 35037793
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update.
Bennett CL; Witherspoon B; Carson KR
Cancer Treat Res; 2022; 184():103-111. PubMed ID: 36449191
[TBL] [Abstract][Full Text] [Related]
13. Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: neuropathological findings and results of mefloquine treatment.
Sano Y; Nakano Y; Omoto M; Takao M; Ikeda E; Oga A; Nakamichi K; Saijo M; Maoka T; Sano H; Kawai M; Kanda T
Intern Med; 2015; 54(8):965-70. PubMed ID: 25876582
[TBL] [Abstract][Full Text] [Related]
14. Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card.
Sarsour K; Beckley-Kartey S; Melega S; Odueyungbo A; Kirchner P; Khalife N; Bangs J
Pharmacol Res Perspect; 2020 Feb; 8(1):e00555. PubMed ID: 31911839
[TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance and PML in the oncology setting.
Bennett CL
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S13-7. PubMed ID: 22123927
[TBL] [Abstract][Full Text] [Related]
16. [Fatal neurological side effect of anti-CD20 antibody treatment].
Schmidt K; Skusa R; Großmann A
Inn Med (Heidelb); 2023 Feb; 64(2):193-196. PubMed ID: 36422661
[TBL] [Abstract][Full Text] [Related]
17. Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy.
Tuccori M; Focosi D; Blandizzi C; Pelosini M; Montagnani S; Maggi F; Pistello M; Antonioli L; Fornai M; Pepe P; Rossi G; Petrini M
Oncologist; 2010; 15(11):1214-9. PubMed ID: 21041380
[TBL] [Abstract][Full Text] [Related]
18. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Faulkner M
Expert Opin Drug Saf; 2015; 14(11):1737-48. PubMed ID: 26394704
[TBL] [Abstract][Full Text] [Related]
19. Posterior Fossa Progressive Multifocal Leukoencephalopathy Secondary to Rituximab.
Guduru M; Bendi VS; Bebawy MS; Bande D; Matta A
Cureus; 2020 Oct; 12(10):e10888. PubMed ID: 33178540
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
